JP2004501870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501870A5 JP2004501870A5 JP2001579823A JP2001579823A JP2004501870A5 JP 2004501870 A5 JP2004501870 A5 JP 2004501870A5 JP 2001579823 A JP2001579823 A JP 2001579823A JP 2001579823 A JP2001579823 A JP 2001579823A JP 2004501870 A5 JP2004501870 A5 JP 2004501870A5
- Authority
- JP
- Japan
- Prior art keywords
- hcl
- antitumor
- composition
- acetate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/561,917 US6462017B1 (en) | 2000-05-01 | 2000-05-01 | Method of reducing side effects of chemotherapy in cancer patients |
| PCT/US2001/012696 WO2001082949A2 (en) | 2000-05-01 | 2001-04-19 | Method of reducing side effects of chemotherapy in cancer patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501870A JP2004501870A (ja) | 2004-01-22 |
| JP2004501870A5 true JP2004501870A5 (enExample) | 2005-07-07 |
Family
ID=24244042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001579823A Pending JP2004501870A (ja) | 2000-05-01 | 2001-04-19 | ガン患者における化学療法の副作用を軽減させる方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6462017B1 (enExample) |
| EP (1) | EP1357935B1 (enExample) |
| JP (1) | JP2004501870A (enExample) |
| CN (1) | CN100441221C (enExample) |
| AT (1) | ATE348630T1 (enExample) |
| AU (2) | AU5547501A (enExample) |
| CA (1) | CA2407238C (enExample) |
| DE (1) | DE60125417D1 (enExample) |
| WO (1) | WO2001082949A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440555A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| UA77999C2 (en) * | 2001-12-10 | 2007-02-15 | Thymosin-alpha 1 for treatment of malignant glioblastoma | |
| CN100501400C (zh) * | 2002-11-25 | 2009-06-17 | 希克龙制药公司 | 使用α胸腺素防护辐射损伤的方法 |
| JP2006213645A (ja) * | 2005-02-03 | 2006-08-17 | Hokkaido Univ | ゲラニルゲラニルアセトンと抗癌剤とを組み合わせてなる医薬 |
| JP5044150B2 (ja) * | 2005-08-05 | 2012-10-10 | Ｔｏｔｏ株式会社 | 光照射により薬効を消失させる医薬二酸化チタン複合材 |
| US20070292392A1 (en) * | 2006-06-15 | 2007-12-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
| US8017129B2 (en) * | 2006-06-15 | 2011-09-13 | SciClone Pharmaceuticals International Ltd | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
| US20080253997A1 (en) * | 2007-03-27 | 2008-10-16 | Perscitus Biosciences, Llc | Compositions and methods for protecting cells from toxic exposures |
| US20080300166A1 (en) * | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
| JP2011506467A (ja) * | 2007-12-14 | 2011-03-03 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 |
| EP2259844A4 (en) * | 2008-03-05 | 2012-02-01 | Vicus Therapeutics Llc | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES |
| EP2675272A4 (en) * | 2011-02-09 | 2015-03-11 | Sciclone Pharmaceuticals Inc | THYMOSINE ALPHA PEPTIDE FOR THE PREVENTION, TREATMENT AND TREATMENT OF INFECTIONS |
| US20140322320A1 (en) * | 2013-04-24 | 2014-10-30 | Uday Saxena | Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| RU2726131C2 (ru) | 2015-05-22 | 2020-07-09 | Дмитрий Дмитриевич Генкин | Внеклеточная днк в качестве терапевтической мишени при нейродегенерации |
| JP6761857B2 (ja) * | 2015-10-29 | 2020-09-30 | シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 抗癌療法の安全性および有効性を改善する方法 |
| CN107137684A (zh) * | 2017-05-23 | 2017-09-08 | 山西中医学院 | 一种用于胃肠疾病的药物组合物及其制备方法和用途 |
| FR3074042A1 (fr) | 2017-11-29 | 2019-05-31 | Galderma Research & Development | Kit pour son utilisation dans la prevention et/ou le traitement des effets secondaires lies a une therapie anticancereuse |
| US11905522B2 (en) | 2018-01-16 | 2024-02-20 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| CN109820859A (zh) * | 2019-04-09 | 2019-05-31 | 上海市计划生育科学研究所 | 醋酸诺美孕酮在制备预防或治疗呕吐或改善恶病质的药物中的应用 |
| IT202300020361A1 (it) | 2023-10-03 | 2025-04-03 | Blue Hydrogen Science S R L | Nuovi utilizzi di soluzioni acquose ad elevata concentrazione di idrogeno |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US527393A (en) * | 1894-10-09 | Busy-test for multiple switchboards | ||
| US5273963A (en) | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
| US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
-
2000
- 2000-05-01 US US09/561,917 patent/US6462017B1/en not_active Expired - Lifetime
-
2001
- 2001-04-19 AU AU5547501A patent/AU5547501A/xx active Pending
- 2001-04-19 DE DE60125417T patent/DE60125417D1/de not_active Expired - Lifetime
- 2001-04-19 WO PCT/US2001/012696 patent/WO2001082949A2/en not_active Ceased
- 2001-04-19 AT AT01928641T patent/ATE348630T1/de not_active IP Right Cessation
- 2001-04-19 EP EP01928641A patent/EP1357935B1/en not_active Expired - Lifetime
- 2001-04-19 JP JP2001579823A patent/JP2004501870A/ja active Pending
- 2001-04-19 CN CNB018089070A patent/CN100441221C/zh not_active Expired - Lifetime
- 2001-04-19 AU AU2001255475A patent/AU2001255475B2/en not_active Ceased
- 2001-04-19 CA CA2407238A patent/CA2407238C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2407238A1 (en) | The use of thymosin alpha 1 to reduce the side effects of chemotherapy in cancer patients | |
| CN104818414B (zh) | 一种具有多孔结构的金属植骨材料及其制备和应用 | |
| DE3007446A1 (de) | Element zur implantation in koerpergewebe | |
| JP2017519753A5 (enExample) | ||
| RU2008117295A (ru) | Новые пиразолопиримидины как ингибиторы циклинзависимых киназ | |
| PE44799A1 (es) | Antagonistas del receptor de vitronectina | |
| HU0201043D0 (enExample) | ||
| CN111155013B (zh) | 一种医用三维打印合金材料及其制备方法 | |
| CN111195374A (zh) | 一种具有骨诱导活性的医用可降解镁-锌-镁复合棒材及其制备方法 | |
| AU2001255475A1 (en) | Method of reducing side effects of chemotherapy in cancer patients | |
| AU2001255475A2 (en) | Method of reducing side effects of chemotherapy in cancer patients | |
| CN104762542A (zh) | 生物医用可降解吸收Mg-Sr-Cu合金材料及制备方法和应用 | |
| JP2023145674A5 (enExample) | ||
| Chen et al. | Biodegradable Zinc‐Based Alloys for Guided Bone Regeneration Membranes: Feasibility, Current Status, and Future Prospects | |
| JP2005508322A5 (enExample) | ||
| DE3206726A1 (de) | Pharmakadepot | |
| NZ223720A (en) | Dsrna/lymphokine therapy optionally using cyclooxygenase activator to increase the levels of nk (natural killer) and lak (lymphokine activated killer) cells | |
| CA2461227A1 (en) | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | |
| CN104511051B (zh) | 一种预防和治疗骨感染的复合骨水泥及其制备方法 | |
| Grevstad et al. | Effect of doxycycline on surgically induced osteoclast recruitment in the rat | |
| De Vos et al. | Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer | |
| US11345981B2 (en) | Biodegradable metal alloy with multiple properties | |
| EP1066065A1 (de) | Bio-zemente mit verbesserten eigenschaften | |
| JP2008222506A (ja) | 生物学的活性物質含有リン酸八カルシウム系結晶、その製造方法及びそれを含む医薬組成物 | |
| IL299673A (en) | Anticancer activity of paraborate salts |